Skip to main content

Table 3 Summary of clinicopathologic features, treatment, and outcome of those who failed primary treatment

From: Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institution

Pt's
ID
Age Histology/Stage Primary treatment Outcome of primary treatment Time to
relapse
(months)
Site of
Relapse/
progression
Salvage treatment Outcome
1 18 Choriocarcinoma/
Stage IV
TAH + BSO
+ staging op
+ BEP chemo.
CR 4 Brain EMA-CO
chemo.
DOD
2 25 Immature teratoma/
Stage Ic
USO
+ staging op
CR 11 PAN BEP chemo NED
at age 33
3 22 Mixed germ cell
tumor/Stage IIIa
TAH + BSO
+ staging op
+ EP chemo
CR 12 Mesentery EP chemo NED
at age 33
4 19 EST/Stage IIIa TAH + BSO
+ staging op
+ CP chemo.
CR 7 Mesentery EP chemo. NED
at age 29
5 29 EST/Stage IIIc TAH + BSO
+ staging op
+ EP chemo.
CR 6 Pelvic lymph
node
VBP chemo. NED
at age 36
6 65 Mixed germ cell
tumor/Stage IIIc
TAH + BSO
+ staging op
+ EP chemo
Progressi-on   Liver Cisplatin + Paclitaxel
chemo.
DOD
  1. TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; USO, unilateral salpingo-oophorectomy; EMA-CO, etoposide, methotraxate, actinomycin-D, vincristine, and cyclophosphamide; BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; CP, cisplatin and cyclophophamide; VBP, vinblastine, bleomycin, and cisplatin; CR, complete remission; PAN, paraaortic lymph node; DOD, died of disease; NED, no evidence of disease.